Purpose: Cardiac positron emission tomography (PET) images usually show two kinds of artifacts: the limited resolution of PET leads to partial volume effects and the motion of the heart induces blurring. These phenomena degrade the PET images and induce errors in the quantification. One method of reducing this problem is to use gated PET data. However, the reduction of information per phase leads to an increase in noise on the reconstructed images. Alternatively, the PET data have to be corrected for motion and partial volume effects.

Methods: Optical flow methods have been shown to accurately estimate the motion between PET image frames. These methods assume that the brightness of the objects remains constant between the frames. This condition is not fulfilled in cardiac PET data because the brightness of the cardiac muscle tissue (myocardium) is not accurately resolved due to the partial volume effect. Therefore, the use of a newly developed optical flow method based upon the conservation of mass condition is proposed to correct the cardiac PET data. Mass conservation is applicable to PET images as the total activity in the field of view may be assumed to remain almost constant, if the data are precorrected for radioactive decay. Two variants of the method using the quadratic and the nonquadratic penalization are presented. The methods were evaluated with respect to correlation coefficient, myocardial thickness and the blood pool activity in the left ventricle on phantom data and on 14 patient image volumes.

Results: The proposed methods showed that the cardiac motion can be efficiently corrected despite partial volume effects. The correlation coefficient between the image volumes increased from 0.87 to 0.98 on average. The change in myocardial thickness was reduced from 28% to 3%. The variation in blood pool activity was reduced from 80% to 8%. The algorithm needed only about 4 s for execution.

Conclusions: A mass preserving optical flow method of cardiac motion correction in 3D PET data has been presented and tested on phantom as well as patient data. The results show that the motion was corrected for all datasets effectively.

Download full-text PDF

Source
http://dx.doi.org/10.1118/1.4770276DOI Listing

Publication Analysis

Top Keywords

pet data
20
optical flow
16
partial volume
16
flow method
12
cardiac motion
12
pet images
12
pet
10
method cardiac
8
motion correction
8
volume effects
8

Similar Publications

[A comparative study on the diagnostic value of F-PSMA PET/CT PRIMARY score and PSMA expression score for clinically significant prostate cancer].

Zhonghua Yi Xue Za Zhi

January 2025

Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing100730, China.

To compare the diagnostic value of fluorine 18-labelled prostate-specific membrane antigen (PSMA) PET/CT PRIMARY score and PSMA expression score for clinically significant prostate cancer (csPCa). The data of 70 patients with prostate cancer who underwent radical prostatectomy at Beijing Hospital from February 1, 2019 to February 29, 2024 were retrospectively analyzed. All patients underwent whole body F-PSMA PET/CT examination before surgery and pathological large sections of prostate specimens were made after surgery.

View Article and Find Full Text PDF

To establish and validate a nomogram based on clinical characteristics and metabolic parameters derived from F-fluorodeoxyglucose positron emission tomography and computed tomography (F-FDG PET/CT) for prediction of high-grade patterns (HGP) in invasive lung adenocarcinoma. The clinical and PET/CT image data of 311 patients who were confirmed invasive lung adenocarcinoma and underwent pre-treatment F-FDG PET/CT scan in Beijing Hospital between October 2017 and March 2022 were retrospectively collected. The enrolled patients were divided into HGP group (196 patients) and non-HGP group (115 patients) according to the presence and absence of HGP.

View Article and Find Full Text PDF

Quantitative and Visual Benefits of Data-Driven Motion Correction on Oncologic PET/CT: A Prospective Cross-sectional Study.

Acad Radiol

January 2025

Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd, St. Louis, MO 63110 (S.I., M.A.T., M.I., C.S., R.L., A.H., R.L.W., T.J.F.). Electronic address:

Rationale And Objective: Conventional positron emission tomography (PET) respiratory gating utilizes a fraction of acquired PET counts (i.e., optimal gate [OG]), whereas elastic motion correction with deblurring (EMCD) utilizes all PET counts to reconstruct motion-corrected images without increasing image noise.

View Article and Find Full Text PDF

Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort.

J Prev Alzheimers Dis

February 2025

Turku PET Centre, University of Turku, Turku, Finland; Turku PET Centre, Turku University Hospital, Turku, Finland; Department of Geriatrics, Turku University Hospital, Wellbeing services county of Southwestern Finland, Finland.

Background: Dementia is a significant cause of disability and dependency. Persons with high dementia risk but intact cognition will benefit from preventive interventions.

Objectives: The aim was to validate dementia risk score Cardiovascular Risk Factors, Aging and Incidence of Dementia (CAIDE) in a national population-based cohort with data on age, education, hypertension, obesity, hyperlipidemia and physical activity.

View Article and Find Full Text PDF

Flurpiridaz F 18: First Approval.

Am J Cardiovasc Drugs

January 2025

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!